Published in Mod Pathol on March 01, 1992
Latency is not an inevitable outcome of infection with Pneumocystis carinii. Infect Immun (1993) 1.38
Evaluation of diagnostic value and epidemiological implications of PCR for Pneumocystis carinii in different immunosuppressed and immunocompetent patient groups. J Clin Microbiol (2000) 1.15
Usefulness of PCR for diagnosis of Pneumocystis carinii pneumonia in different patient groups. J Clin Microbiol (1997) 0.91
Simple and rapid two-step polymerase chain reaction for diagnosis of Pneumocystis carinii infection. J Clin Microbiol (1993) 0.88
Use of semiquantitative PCR to assess onset and treatment of Pneumocystis carinii infection in rat model. J Clin Microbiol (1995) 0.88
A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med (2005) 17.06
Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS (2000) 8.86
A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med (1996) 7.60
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA (2000) 6.49
Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA (1997) 6.35
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA (1996) 5.29
HIV viral load markers in clinical practice. Nat Med (1996) 4.78
Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA (1998) 4.61
HIV-1 protease inhibitors. A review for clinicians. JAMA (1997) 4.34
Simultaneous genotyping and species identification using hybridization pattern recognition analysis of generic Mycobacterium DNA arrays. Genome Res (1998) 3.85
A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J Clin Invest (1998) 2.88
Detection and quantification of human immunodeficiency virus RNA in patient serum by use of the polymerase chain reaction. J Infect Dis (1991) 2.86
Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial. Ann Intern Med (1990) 2.40
The impact of active herpes simplex virus infection on human immunodeficiency virus load. J Infect Dis (1997) 2.31
A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J Infect Dis (1993) 2.28
Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J Infect Dis (1994) 2.26
Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N Engl J Med (2001) 2.08
Human immunodeficiency virus type 1 populations in blood and semen. J Virol (1998) 1.99
A meta-analytic evaluation of the polymerase chain reaction for the diagnosis of HIV infection in infants. JAMA (1996) 1.97
Biological variation and quality control of plasma human immunodeficiency virus type 1 RNA quantitation by reverse transcriptase polymerase chain reaction. J Clin Microbiol (1993) 1.94
Reduction in plasma human immunodeficiency virus ribonucleic acid after dideoxynucleoside therapy as determined by the polymerase chain reaction. J Clin Invest (1991) 1.85
Divergent transcriptional regulation among expanding human immunodeficiency virus type 1 subtypes. J Virol (1997) 1.82
Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team. J Infect Dis (1995) 1.79
Performance characteristics for the quantitation of plasma HIV-1 RNA using branched DNA signal amplification technology. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.78
Antibiotic-associated pseudomembranous enteritis due to Clostridium difficile. Clin Infect Dis (1994) 1.68
Polymerase chain reaction for the diagnosis of HIV infection in adults. A meta-analysis with recommendations for clinical practice and study design. Ann Intern Med (1996) 1.50
Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe. J Virol (1997) 1.48
Differences between women and men in adverse events and CD4+ responses to nucleoside analogue therapy for HIV infection. The Aids Clinical Trials Group 175 Team. J Acquir Immune Defic Syndr (2000) 1.45
HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine-treated patients. J Acquir Immune Defic Syndr (1994) 1.44
Genital ulcers and transmission of HIV among couples in Zimbabwe. AIDS (1989) 1.43
Cytomegalovirus viremia detected by molecular hybridization and electron microscopy. Ann Intern Med (1984) 1.43
Detection of human immunodeficiency virus DNA and RNA in semen by the polymerase chain reaction. J Infect Dis (1991) 1.43
Possible beneficial effects of neutralizing antibodies and antibody-dependent, cell-mediated cytotoxicity in human immunodeficiency virus infection. AIDS Res Hum Retroviruses (1990) 1.39
Dried-plasma transport using a novel matrix and collection system for human immunodeficiency virus and hepatitis C virus virologic testing. J Clin Microbiol (2009) 1.32
Nonisotopic hybridization assay for determination of relative amounts of genotypic human immunodeficiency virus type 1 zidovudine resistance. J Clin Microbiol (1995) 1.31
An evaluation of dipstick-dot immunoassay in the detection of antibodies to HIV-1 and 2 in Zimbabwe. Trop Med Int Health (1997) 1.26
Risk factors for HIV infection at enrollment in an urban male factory cohort in Harare, Zimbabwe. J Acquir Immune Defic Syndr Hum Retrovirol (1996) 1.23
Primary subtype C HIV-1 infection in Harare, Zimbabwe. J Acquir Immune Defic Syndr Hum Retrovirol (1999) 1.22
Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy. Ann Intern Med (1994) 1.21
Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis (1998) 1.20
Sequence and drug susceptibility of subtype C protease from human immunodeficiency virus type 1 seroconverters in Zimbabwe. AIDS Res Hum Retroviruses (1999) 1.18
Stabilities of quantitative plasma culture for human immunodeficiency virus, RNA, and p24 antigen from samples collected in VACUTAINER CPT and standard VACUTAINER tubes. J Clin Microbiol (1994) 1.16
Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic response. J Acquir Immune Defic Syndr (2000) 1.15
Detection of human immunodeficiency virus type 1 in semen: effects of disease stage and nucleoside therapy. J Infect Dis (1993) 1.14
Quantification and comparison of HIV-1 proviral load in peripheral blood mononuclear cells and isolated CD4+ T cells. J Acquir Immune Defic Syndr (1993) 1.14
Comparative effectiveness of dried plasma HIV-1 viral load testing in Brazil using ViveST for sample collection. J Clin Virol (2010) 1.13
Lethal infection with murine cytomegalovirus after early viral replication in the spleen. J Infect Dis (1983) 1.12
Plasma viremia in human immunodeficiency virus infection: relationship to stage of disease and antiviral treatment. J Acquir Immune Defic Syndr (1992) 1.09
Bordetella bronchiseptica bacteremia. West J Med (1984) 1.06
Characterization of the HIV-1 specific humoral immune response during highly active antiretroviral therapy (HAART). J Acquir Immune Defic Syndr (2001) 1.05
Variability and prognostic values of virologic and CD4 cell measures in human immunodeficiency virus type 1-infected patients with 200-500 CD4 cells/mm(3) (ACTG 175). AIDS Clinical Trials Group Protocol 175 Team. J Infect Dis (1998) 1.04
Human immunodeficiency virus type 1 quantitative cell microculture as a measure of antiviral efficacy in a multicenter clinical trial. J Infect Dis (1995) 1.04
Genotypic correlates of a virologic response to stavudine after zidovudine monotherapy. J Acquir Immune Defic Syndr (2001) 1.02
Decrease in HIV provirus in peripheral blood mononuclear cells during zidovudine and human rIL-2 administration. J Acquir Immune Defic Syndr (1992) 1.00
Zidovudine treatment in patients with primary (acute) human immunodeficiency virus type 1 infection: a randomized, double-blind, placebo-controlled trial. DATRI 002 Study Group. Division of AIDS Treatment Research Initiative. J Infect Dis (1998) 0.99
Evaluation of Chiron HIV-1/HIV-2 recombinant immunoblot assay. J Clin Microbiol (1996) 0.99
Decreased human immunodeficiency virus type 1 plasma viremia during antiretroviral therapy reflects downregulation of viral replication in lymphoid tissue. Proc Natl Acad Sci U S A (1995) 0.99
Syphilis serology and HIV infection in Harare, Zimbabwe. Sex Transm Infect (1999) 0.98
Zidovudine susceptibility testing of human immunodeficiency virus type 1 (HIV) clinical isolates. J Virol Methods (1993) 0.97
Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. AIDS Clinical Trials Group Protocol 175 Team. J Infect Dis (1998) 0.96
HIV type 1 envelope subtype C sequences from recent seroconverters in Zimbabwe. AIDS Res Hum Retroviruses (2000) 0.96
The role of alpha and beta platelet-derived growth factor receptor in the vascular response to injury in nonhuman primates. Arterioscler Thromb Vasc Biol (1999) 0.96
HIV viral load quantification, HIV resistance, and antiretroviral therapy. AIDS Clin Rev (1996) 0.95
Sexual behavior and risk factors for HIV infection in a group of male factory workers who donated blood in Harare, Zimbabwe. J Acquir Immune Defic Syndr (1992) 0.95
Clinical utility of viral load measurements in individuals with chronic hepatitis C infection on antiviral therapy. J Viral Hepat (2005) 0.93
Both serum HIV type 1 RNA levels and CD4+ lymphocyte counts predict clinical outcome in HIV type 1-infected subjects with 200 to 500 CD4+ cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. AIDS Res Hum Retroviruses (2000) 0.92
HIV-1 reverse transcriptase codon 215 mutation in plasma RNA: immunologic and virologic responses to zidovudine. The AIDS Clinical Trials Group Study 175 Virology Team. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 0.91
Failure of short-term CD4-PE40 infusions to reduce virus load in human immunodeficiency virus-infected persons. J Infect Dis (1994) 0.90
Quantitative RNA and DNA gene amplification can rapidly monitor HIV infection and antiviral activity in cell cultures. PCR Methods Appl (1992) 0.89
Antiretroviral monotherapy in early stage human immunodeficiency virus disease has no detectable effect on virus load in peripheral blood and lymph nodes. J Infect Dis (1996) 0.88
Decreased medical expenditures for care of HIV-seropositive patients. The impact of highly active antiretroviral therapy at a US Veterans Affairs Medical Center. Pharmacoeconomics (1999) 0.87
Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapy. J Infect Dis (2001) 0.87
Microbial flora of the lower genital tract of women in labour at Harare Maternity Hospital. The Puerperal Sepsis Study Group. Cent Afr J Med (1989) 0.86
Bayesian network analysis of resistance pathways against HIV-1 protease inhibitors. Infect Genet Evol (2006) 0.86
Nosocomial adenovirus infections: molecular epidemiology of an outbreak due to adenovirus 3a. J Infect Dis (1988) 0.86
Detection of Kaposi's sarcoma-associated herpesvirus in peripheral blood cells in human immunodeficiency virus infection: association with Kaposi's sarcoma, CD4 cell count, and HIV RNA levels. AIDS Res Hum Retroviruses (1999) 0.86
Report of sexually transmitted diseases by HIV infected men during follow up: time to target the HIV infected? Sex Transm Infect (2000) 0.86
Vaginal flora of women admitted to hospital with signs of sepsis following normal delivery, cesarean section or abortion. The Puerperal Sepsis Study Group. Cent Afr J Med (1989) 0.84
Neuromuscular function in HIV infection: analysis of a placebo-controlled combination antiretroviral trial. AIDS Clinical Group 175/801 Study Team. AIDS (1998) 0.84
Deferral of blood donors with risk factors for HIV infection saves lives and money in Zimbabwe. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 0.83
Antimicrobial resistance in gonococci isolated from patients and from commercial sex workers in Harare, Zimbabwe. Int J Antimicrob Agents (1997) 0.82
Chlamydia trachomatis in symptomatic and asymptomatic men: detection in urine by enzyme immunoassay. Cent Afr J Med (2000) 0.80
The sulfone syndrome in a patient receiving dapsone prophylaxis for Pneumocystis carinii pneumonia. West J Med (1992) 0.80
Polyethylene glycol-modified interleukin-2 and thymosin alpha 1 in human immunodeficiency virus type 1 infection. J Infect Dis (1996) 0.80
Polymerase chain reaction detection of Haemophilus ducreyi DNA. Sex Transm Infect (1998) 0.79
Successful treatment of murine cytomegalovirus disease does not prevent latent virus infection. J Lab Clin Med (1986) 0.79
Concurrent outbreaks with co-infection of norovirus and Clostridium difficile in a long-term-care facility. Epidemiol Infect (2013) 0.79
Acute and chronic immune biomarker changes during interferon/ribavirin treatment in HIV/HCV co-infected patients. J Viral Hepat (2014) 0.78
Quantitative relationship between platelet count and plasma virion HIV RNA. AIDS (1996) 0.78
Detection of antibodies to Pneumocystis carinii in bronchoalveolar lavage fluid by immunoreactivity to Pneumocystis carinii within alveoli, granulomas, and disseminated sites. Mod Pathol (1992) 0.78
A pilot trial of indinavir, ritonavir, didanosine, and lamivudine in a once-daily four-drug regimen for HIV infection. J Acquir Immune Defic Syndr (2001) 0.77
Multinodular polymyositis in a patient with human immunodeficiency and hepatitis C virus coinfection. Muscle Nerve (2001) 0.76
Meta-analysis of five randomized controlled trials comparing continuation of zidovudine versus switching to didanosine in HIV-infected individuals. Antivir Ther (1997) 0.76